IRLAB publishes the annual report for 2019
IRLAB announced today that the company’s annual report for fiscal year 2019, in Swedish, is published and available on the company’s website.
“We now have two drug candidates with new mechanisms of action that have delivered very positive results in Phase IIa studies for Parkinson’s; This confirms the power of innovation in our research platform ISP. We are now entering the “develop for launch” phase with mesdopetam and IRL752 and continues the development of our preclinical projects toward Phase I studies,” says Nicholas Waters, CEO.
IRLAB’s annual report for 2019, in Swedish, is attached to this press release and is also available as a downloadable PDF on IRLAB’s website, www.irlab.se/investor-relations/financial-reports/.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and IRL752, both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, firstname.lastname@example.org, +46 (0)8528 00 399. More information on www.irlab.se.